MDNA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 mar 2024 @ 21:00):

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases...

Stats
Dagens volum	1.19M
Gjennomsnittsvolum	0.00
Markedsverdi	10.93M
EPS	$0 ( 2024-02-05 )
Neste inntjeningsdato	( $0 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.740
ATR14	$0.0420 (11.51%)

Volum Korrelasjon

Lang: -0.14 (neutral)

Kort: 0.63 (weak)

Signal:(57.847) Neutral

Medicenna Therapeutics Korrelasjon

10 Mest positive korrelasjoner
RTPY	0.847
CRCT	0.843
SPCB	0.84
EMBCV	0.838
SQQQ	0.834
DISH	0.831
DSWL	0.828
SGML	0.825
TC	0.824
BSGM	0.818

10 Mest negative korrelasjoner
INZY	-0.888
VSMV	-0.882
CGNT	-0.881
PPH	-0.872
BLDR	-0.872
PFM	-0.87
FTCS	-0.869
DGRW	-0.869
USMC	-0.867
PATK	-0.867

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Medicenna Therapeutics Korrelasjon - Valuta/Råvare

-0.64
( weak negative )

0.00
( neutral )

-0.49
( neutral )

0.30
( neutral )

0.47
( neutral )

Medicenna Therapeutics Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.0239

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.0239

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.420

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Medicenna Therapeutics

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.